Amarin | AMRN - Gross Profit On Sales


Amarin reported $22.21M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 22.21M 28.15M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
DBV Technologies USD 2.77M 33.21M Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.82B 695M Sep/2025